Vérification…
Traduit automatiquement. Doses et mises en garde : vérifiez l'original en anglais. Lire en anglais

Eliquis

Eliquis is a brand of Apixaban.

ELIQUIS is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1).

Checked against the official label · Updated

Prescription medicine Oral

Eliquis: quick answers

What it is
Factor Xa Inhibitor
Used for
ELIQUIS is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Children
Prescription
Prescription medicine in the United States; rules differ by country.

From the official label (Feb 2025). Your prescription and pharmacist come first.

How to use Eliquis

Ce que dit la notice officielle. Si un médecin vous l'a prescrit, suivez l'ordonnance. La notice de votre boîte prime si elle est différente.

Mise en garde grave : (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. …
Pour qui

ELIQUIS is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. …

Comment le prendre et à quelle fréquence
  • Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation: The recommended dose is 5 mg orally twice daily
  • In patients with at least 2 of the following characteristics: age greater than or equal to 80 years, body weight less than or equal to 60 kg, or serum creatinine greater than or equal to 1.5 mg/dL, the recommended dose is 2.5 mg orally twice daily
  • Prophylaxis of DVT following hip or knee replacement surgery: The recommended dose is 2.5 mg orally twice daily
  • Treatment of DVT and PE: The recommended dose is 10 mg taken orally twice daily for 7 days, followed by 5 mg taken orally twice daily
  • Reduction in the risk of recurrent DVT and PE following initial therapy: The recommended dose is 2.5 mg taken orally twice daily
  • Recommended Dose Reduction of Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation The recommended dose of ELIQUIS for most patients is 5 mg taken orally twice daily
  • The recommended dose of ELIQUIS is 2.5 mg twice daily in patients with at least two of the following characteristics: age greater than or equal to 80 years body weight less than or equal to 60 kg serum creatinine greater than or equal to 1.5 mg/dL Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery The recommended dose of ELIQUIS is 2.5 mg taken orally twice daily
  • The initial dose should be taken 12 to 24 hours after surgery
  • In patients undergoing hip replacement surgery, the recommended duration of treatment is 35 days. …
Strengths it comes in

2.5 mg, yellow, round, biconvex, film-coated tablets with “893” debossed on one side and “2½” on the other side. 5 mg, pink, oval-shaped, biconvex, film-coated tablets with “894” debossed on one side and “5” on the other side. Tablets: 2.5 mg and 5 mg (3)

Children
  • Safety and effectiveness
  • In pediatric patients have not been established
Older adults

Of the total subjects in the ARISTOTLE and AVERROES clinical studies, >69% were 65 years of age and older, and >31% were 75 years of age and older. In the ADVANCE-1, ADVANCE-2, and ADVANCE-3 clinical studies, 50% of subjects were 65 years of age and older, while 16% were 75 years of age and older. In the AMPLIFY and AMPLIFY-EXT clinical studies, >32% of subjects were 65 years of age and older and >13% were 75 years of age and older. …

While you are taking it
  • Advise patients to read the FDA-approved patient labeling (Medication Guide)
  • Advise patients of the following: Not to discontinue ELIQUIS without talking to their physician first
  • That it might take longer than usual for bleeding to stop, and they may bruise or bleed more easily when treated with ELIQUIS
  • Advise patients about how to recognize bleeding or symptoms of hypovolemia and of the urgent need to report any unusual bleeding to their physician. …
Talk to a doctor first if

ELIQUIS is contraindicated in patients with the following conditions: Active pathological bleeding [see Warnings and Precautions (5.2) and Adverse Reactions (6.1) ] Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions) [see Adverse Reactions (6.1) ] Active pathological bleeding (4) Severe hypersensitivity to ELIQUIS (4)

Medicines it may not mix with

Apixaban is a substrate of both CYP3A4 and P-gp. Inhibitors of CYP3A4 and P-gp increase exposure to apixaban and increase the risk of bleeding. Inducers of CYP3A4 and P-gp decrease exposure to apixaban and increase the risk of stroke and other thromboembolic events. Combined P-gp and strong CYP3A4 inhibitors increase blood levels of apixaban. Reduce ELIQUIS dose or avoid coadministration. (2.5 , 7.1 , 12.3) Simultaneous use of combined P-gp and strong CYP3A4 inducers reduces blood levels of apixaban: Avoid concomitant use. …

Warnings

ELIQUIS can cause serious, potentially fatal, bleeding. Promptly evaluate signs and symptoms of blood loss. An agent to reverse the anti-factor Xa activity of apixaban is available. (5.2) Prosthetic heart valves: ELIQUIS use not recommended. (5.4) Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome: ELIQUIS use not recommended. (5.6) 5.1 Increased Risk of Thrombotic Events after Premature Discontinuation Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. …

Effets secondaires possibles

The following clinically significant adverse reactions are discussed in greater detail in other sections of the prescribing information. Increased Risk of Thrombotic Events After Premature Discontinuation [see Warnings and Precautions (5.1) ] Bleeding [see Warnings and Precautions (5.2) ] Spinal/Epidural Anesthesia or Puncture [see Warnings and Precautions (5.3) ] Most common adverse reactions (>1%) are related to bleeding. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . …

Pregnancy and breastfeeding

8.1 Pregnancy Risk Summary The limited available data on ELIQUIS use in pregnant women are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse developmental outcomes. Treatment may increase the risk of bleeding during pregnancy and delivery. …

If you take too much

Overdose of ELIQUIS increases the risk of bleeding [see Warnings and Precautions (5.2) ] . In controlled clinical trials, orally administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice daily for 7 days or 50 mg once daily for 3 days) had no clinically relevant adverse effects. In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20-mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively. …

How to store it

Store at 20°C to 25°C (68°F-77°F); excursions permitted between 15°C and 30°C (59°F-86°F) [see USP Controlled Room Temperature]. …

En cas d'oubli

Prenez-le dès que vous y pensez, sauf s'il est presque l'heure de la dose suivante. Dans ce cas, sautez la dose oubliée. Ne prenez jamais deux doses à la fois pour compenser. Vérifiez votre notice, certains médicaments font exception.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2025-02-03.

How much Eliquis costs

In other countries

Prices in other countries are not what you will pay where you live; they show how prices compare.

Same medicine, other brands

Products with Apixaban as the active ingredient. Names differ between countries.

Registered products

United States (FDA)

EliquisAPIXABAN 5 mg/1 · Tablet, Film Coated · REMEDYREPACK INC.
NDC 70518-4462Label
EliquisAPIXABAN .5 mg/1 · Tablet, For Suspension · E.R. Squibb & Sons, L.L.C.
NDC 0003-1028Label
EliquisAPIXABAN 5 mg/1 · Tablet, Film Coated · Aphena Pharma Solutions - Tennessee, LLC
NDC 71610-662Label
Eliquis 30-day Starter Pack 30-day Starter PackKit · E.R. Squibb & Sons, L.L.C.
NDC 0003-3764Label
EliquisAPIXABAN 2.5 mg/1 · Tablet, Film Coated · E.R. Squibb & Sons, L.L.C.
NDC 0003-0893Label

Nigeria (NAFDAC)

NAFDACEliquis 5 mg Tablets B4-1192

Other countries: check your pack's registration number and we point you to your regulator.

Check your pack of Eliquis

Type the registration number on the pack, or scan it with your camera.

Ou prenez la boîte en photo
Encore 3 vérifications gratuites aujourd'hui Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

Questions about Eliquis

What is in Eliquis?

Eliquis contains Apixaban. Other brands with the same active ingredient work the same way; the dose and strength on your pack are what matter.

What is Eliquis used for?

ELIQUIS is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following init (From the official U.S. FDA label.)

How do I take Eliquis?

Follow your prescription or the leaflet in your pack. The official label says: Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation: The recommended dose is 5 mg orally twice daily. (2.1) In patients with at least 2 of the following characteristics: age greater than or equal to 80 years, body weight less than or equal to 60 kg, or serum creatinine greater than or equal to 1.5 mg/dL, the recommended dose is 2.5 mg orally twi…

Do I need a prescription for Eliquis?

Usually yes. Eliquis is a prescription medicine in most countries. Rules differ by country.

What are the side effects of Eliquis?

The official label lists: The following clinically significant adverse reactions are discussed in greater detail in other sections of the prescribing information. Increased Risk of Thrombotic Events After Premature Discontinuation [see Warnings and Precautions (5.1) ] Bleeding [see Warnings and Precautions (5.2) ] Spinal/Epidural Anesthesia or Puncture [see Warnings and Precautions (5.3) ] Most common a… Tell your doctor about any side effect that bothers you or does not go away.

Can children take Eliquis?

Safety and effectiveness in pediatric patients have not been established. Always use the dose for the child's age or weight on the pack or prescription.

Can I take Eliquis when pregnant or breastfeeding?

8.1 Pregnancy Risk Summary The limited available data on ELIQUIS use in pregnant women are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse developmental outcomes. Treatment may increase the risk of bleeding during pregnancy and delivery. … Ask your doctor or midwife first.

What medicines interact with Eliquis?

Apixaban is a substrate of both CYP3A4 and P-gp. Inhibitors of CYP3A4 and P-gp increase exposure to apixaban and increase the risk of bleeding. Inducers of CYP3A4 and P-gp decrease exposure to apixaban and increase the risk of stroke and other thromboembolic events. Combined P-gp and strong CYP3A4 inhibitors increase blood levels of apixaban. Reduce ELIQUIS dose or avoid coadmi… Use the free interaction checker before combining medicines.

What happens if I take too much Eliquis?

Overdose of ELIQUIS increases the risk of bleeding [see Warnings and Precautions (5.2) ] . In controlled clinical trials, orally administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice daily for 7 days or 50 mg once daily for 3 days) had no clinically releva… Get medical help right away.

How should I store Eliquis?

Store at 20°C to 25°C (68°F-77°F); excursions permitted between 15°C and 30°C (59°F-86°F) [see USP Controlled Room Temperature]. …

How can I check that my Eliquis is genuine?

Scan the registration number on your pack with PillVera (NAFDAC number in Nigeria, NDC in the United States, DIN in Canada), check the expiry date and buy only from licensed pharmacies.

Sources

This page shows what official sources say, in plain words. It is not medical advice: your prescription and your doctor or pharmacist come first. Brand names, strengths and rules differ between countries.